Dr. Priya Nandakumar brings scientific and clinical insight to The Catalyst Brief’s coverage of biomedical research and healthcare innovation. Her work bridges experimental findings, clinical data, and industry strategy, helping readers interpret what new evidence means beyond the lab or trial setting. At The Catalyst Brief, Priya emphasizes translational relevance and long-term implications for patients and pipelines.
160 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Regulatory & PolicyThe U.S. Food and Drug Administration approved 26 new therapies during the first six months of 2026, with oncology and rare diseases accounting for a significant proportion. This report contextualizes these figures, highlights industry implications, and examines the outsize role played by AstraZeneca and Johnson & Johnson during this period.
Dr. Priya NandakumarJul 9, 2026
Biopharmaceutical IndustryIn a significant withdrawal within the biopharmaceutical industry, GSK has opted to terminate its alliance with Alector, originally established to co-develop two promising antibodies targeting neurodegenerative diseases. The inability of both assets to demonstrate meaningful clinical benefit underlines the formidable obstacles inherent in neurology drug development and may reshape the landscape for both organizations.
Dr. Priya NandakumarJul 9, 2026
AI in Drug DiscoveryThe little-known AI biotech Xaira Therapeutics has long operated behind the curtain, backed by over a billion dollars in initial funding. Now, signs indicate that Xaira is shifting its strategy from secrecy to collaboration in a bid to validate an emerging drug pipeline—marking an intriguing inflection point both for the company and the wider industry. With enormous resources and an enigmatic approach, Xaira’s search for external partners raises broader questions about transparency, trust, and validation within the rapidly evolving field of AI-driven pharmaceutical innovation.
Dr. Priya NandakumarJul 8, 2026
Regulatory & PolicyVera Therapeutics has received FDA approval for a new therapy aimed at patients suffering from a type of chronic autoimmune kidney disease. This decision reflects the agency’s ongoing evaluation of therapies for underserved conditions and underscores both clinical promise as well as the administrative landscape shaping patient access.
Dr. Priya NandakumarJul 7, 2026
Regulatory & PolicyThe Centers for Medicare & Medicaid Services has released its draft 2027 outpatient payment rule, proposing fundamental changes that reshape the hospital reimbursement landscape. Key provisions include a 2.4% base rate increase, further restrictions on 340B drug payments, and new site-neutral payment rules for off-campus imaging. Healthcare providers warn that the proposed rule may tip many hospitals into negative margins.
Dr. Priya NandakumarJul 7, 2026
Regulatory & PolicyWithout transparent and detailed access to claims data, the Office of Personnel Management (OPM) cannot adequately address billing inconsistencies or assess the efficiency and fairness of healthcare spending within federal employee health plans. This issue raises substantial concerns about data access, oversight, and accountability in the administration of one of the nation’s largest employer-sponsored health programs.
Dr. Priya NandakumarJul 4, 2026
Regulatory & PolicyMedicare’s renewed proposal to lower payments for 340B drugs is the latest in a string of regulatory controversies surrounding the hotly debated program. With stakeholders divided on the financial impacts to hospitals and the accessibility of care for vulnerable populations, this move is likely to shape policy, hospital strategy, and patient access for years to come.
Dr. Priya NandakumarJul 4, 2026
Biotech InnovationIn a move poised to elevate standards in oncology, Color has introduced a new peer-to-peer component to its Expert Medical Opinion program, enabling oncologists to consult directly with top cancer specialists. This innovation could signal a transformation in how complex cancer diagnoses and treatments are validated and optimized, while amplifying the role of collaborative expertise in personalized care.
Dr. Priya NandakumarJul 3, 2026
Medical TechnologyWith its landmark approval, the Modius Spero becomes the first FDA-cleared neuromodulation device targeting post-traumatic stress disorder. As veterans prepare to gain access through the VA, this breakthrough signals a new era in device-mediated mental health care and raises important questions about accessibility, safety, integration, and the evolving landscape of treatment options.
Dr. Priya NandakumarJul 2, 2026
Biopharmaceutical IndustryFresh research published in The Lancet sheds light on how statins and blood pressure medications are transforming cardiovascular risk profiles among adults with obesity, particularly those over 40. Yet while medical advancements appear to narrow some health disparities for older adults, the outlook for younger generations living with obesity remains complex and concerning. This extensive analysis reviews the new findings, discusses implications for clinical practice and public health, and contextualizes them within the broader fight against obesity.
Dr. Priya NandakumarJul 2, 2026
Biopharmaceutical IndustryServier’s leadership has outlined a clear strategy focused on bold and innovative science rather than blockbuster drugs. At the BIO International Convention, the company shared its rationale for the high-profile acquisitions of Day One Biopharmaceuticals and Edgewise Therapeutics’ neuromuscular business, suggesting a seismic shift in priorities for big pharma.
Dr. Priya NandakumarJul 1, 2026
AI in Drug DiscoveryAI giant Anthropic, after achieving household-name status in technology, is making bold advances into drug development. This move signals a possible industry-wide transformation as tech behemoths join the AI drug discovery race.
Dr. Priya NandakumarJul 1, 2026